USA

The decision positions LANGLARA as only the fourth insulin glargine product available in the US market, joining established products commercialized by Novo Nordisk, Sanofi and Eli Lilly.

If fully developed and commercialized, Huahui Health could receive up to US$1.9 billion in milestone-based payments, in addition to tiered royalties on future global sales.

The acquisition is expected to close by the end of the second quarter or early third quarter of 2026, pending regulatory approvals and customary closing conditions.

Through this expansion, the company aims to strengthen advanced manufacturing capabilities, support workforce development, and generate hundreds of construction-related jobs.

Thermo Fisher’s microbiology unit generated US$645 million in revenue in 2025 and operates within the company’s specialty diagnostics segment.

Terns has now become a wholly owned subsidiary of Merck, and its common stock has ceased trading on the Nasdaq Global Select Market.

The acquisition brings Amicus Therapeutics fully under BioMarin’s global operations, integrating its late-stage and commercial-stage rare disease assets into BioMarin’s established infrastructure.

The transaction is expected to close in the third quarter, after which Esperion will delist from the Nasdaq and operate as a privately held company.

The acquisition gives Lilly access to Ajax’s experimental therapies for myeloproliferative neoplasms (MPNs), a group of rare blood cancers in which the bone marrow produces excessive blood cells.

The Illinois-based drugmaker said the new campus will span 185 acres near Research Triangle Park, one of the country’s leading life sciences clusters.